PMID- 35514877
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2352-9067 (Print)
IS  - 2352-9067 (Electronic)
IS  - 2352-9067 (Linking)
VI  - 40
DP  - 2022 Jun
TI  - Prognosis of patients with active cancer undergoing transcatheter aortic valve 
      implantation: An insight from Japanese multicenter registry.
PG  - 101045
LID - 10.1016/j.ijcha.2022.101045 [doi]
LID - 101045
AB  - BACKGROUND: Malignancy is common in older adults undergoing transcatheter aortic 
      valve implantation (TAVI), and may affect prognosis. The present study aimed to 
      examine whether active cancer affects all-cause mortality rates among patients 
      undergoing TAVI. METHODS: This retrospective study examined data from 1,114 
      consecutive patients treated between April 2010 and June 2019. Patients with life 
      expectancy of <1 year due to non-cardiac causes were excluded. RESULTS: Active 
      cancer was defined as cancer under treatment or cured within 1 year, and was 
      recognized in 62 patients (5.6%) with (n = 17) and without (n = 45) metastases. 
      In multivariate analysis, being female (hazard ratio [HR] 0.55, 95% confidence 
      interval [CI] 0.39-0.77, p < 0.001), body mass index (BMI) (HR = 0.92 per 
      1 kg/m(2) increase, 95% CI 0.87-0.97, p = 0.001), New York Heart Association 
      (NYHA) class III/IV (HR = 1.53, 95% CI 1.06-2.20, p = 0.022), atrial fibrillation 
      (HR = 2.40, 95% CI 1.70-3.38, p < 0.001), albumin levels (HR = 0.41 per 1-g/dl, 
      95% CI 0.30-0.57, p < 0.001), and cancer metastasis (HR = 5.28, 95% CI 1.86-14.9, 
      p = 0.001) were associated with all-cause mortality after TAVI. CONCLUSION: In 
      patients undergoing TAVI, being female, high BMI, NYHA class III/IV, atrial 
      fibrillation, albumin levels, and cancer metastasis were factors associated with 
      mortality. Meanwhile, active cancer without metastasis was not associated with 
      increased mortality rates. These findings would help clinical decision-making by 
      patients and physicians.Clinical trial registration: UMIN000031133.
CI  - (c) 2022 The Author(s).
FAU - Kojima, Yoshimasa
AU  - Kojima Y
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
AD  - Department of Cardiology, Toho University, Tokyo, Japan.
FAU - Higuchi, Ryosuke
AU  - Higuchi R
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Hagiya, Kenichi
AU  - Hagiya K
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Saji, Mike
AU  - Saji M
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Takamisawa, Itaru
AU  - Takamisawa I
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Iguchi, Nobuo
AU  - Iguchi N
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Takanashi, Shuichiro
AU  - Takanashi S
AD  - Department of Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Doi, Shinichiro
AU  - Doi S
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo, Japan.
FAU - Okazaki, Shinya
AU  - Okazaki S
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of 
      Medicine, Tokyo, Japan.
FAU - Sato, Kei
AU  - Sato K
AD  - Department of Cardiology, Mie University Hospital, Mie, Japan.
FAU - Tamura, Harutoshi
AU  - Tamura H
AD  - Department of Cardiology, Pulmonology and Nephrology, Yamagata University 
      Hospital, Yamagata, Japan.
FAU - Takayama, Morimasa
AU  - Takayama M
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Ikeda, Takanori
AU  - Ikeda T
AD  - Department of Cardiology, Toho University, Tokyo, Japan.
FAU - Isobe, Mitsuaki
AU  - Isobe M
AD  - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220502
PL  - Ireland
TA  - Int J Cardiol Heart Vasc
JT  - International journal of cardiology. Heart & vasculature
JID - 101649525
PMC - PMC9066355
OTO - NOTNLM
OT  - AS, aortic stenosis
OT  - CI, confidence interval
OT  - CT, computed tomography
OT  - Cancer
OT  - Carcinoma
OT  - HR, hazard ratio
OT  - Malignancy
OT  - Mortality
OT  - NYHA, New York Heart Association
OT  - SAVR, surgical aortic valve replacement
OT  - TAVI, transcatheter aortic valve implantation
OT  - Transcatheter aortic valve replacement
COIS- Dr Takamisawa is a clinical proctor of Edwards Lifesciences and Medtroic. The 
      other authors have no conflict of interest regarding this article.
EDAT- 2022/05/07 06:00
MHDA- 2022/05/07 06:01
PMCR- 2022/05/02
CRDT- 2022/05/06 05:30
PHST- 2022/04/08 00:00 [received]
PHST- 2022/04/23 00:00 [revised]
PHST- 2022/04/26 00:00 [accepted]
PHST- 2022/05/06 05:30 [entrez]
PHST- 2022/05/07 06:00 [pubmed]
PHST- 2022/05/07 06:01 [medline]
PHST- 2022/05/02 00:00 [pmc-release]
AID - S2352-9067(22)00094-X [pii]
AID - 101045 [pii]
AID - 10.1016/j.ijcha.2022.101045 [doi]
PST - epublish
SO  - Int J Cardiol Heart Vasc. 2022 May 2;40:101045. doi: 10.1016/j.ijcha.2022.101045. 
      eCollection 2022 Jun.